Dr Judith Reinhard is Chief Scientific Officer and Member of the Board at SEAL Therapeutics AG, a spin-off of Biozentrum, University of Basel, pioneering SEAL technology for therapeutic delivery. Trained in molecular biology and neurosciences, she co-developed the core SEAL platform that underpins the company’s approach of delivering specifically designed linker proteins that compensate for the missing laminin-alpha 2 in the muscle fibres.

In parallel with her role at SEAL Therapeutics, Dr Reinhard serves as a Research Associate at the Biozentrum, University of Basel, where her work bridges academic research and translational applications. Her scientific contributions span the molecular mechanisms of protein engineering and delivery, and she brings deep expertise in developing and validating novel biologics for clinical translation.